The study found Detroit has sunk by approximately 10.2 millimeters, or about 0.4 inches, from 2015-2021, based on an average land subsidence rate of 1.7 millimeters per year, said Leonard Ohenhen, the ...

Preliminary results from the Phase 2 iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population ...

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the progression of Type 1 diabetes by targeting an inflammation-related ...

In the 28-day, 36-subject MAD portion of the study, a clear dose-responsive trend ... with its novel 3:1 ratio between GLP-1R and GCGR at the 32 mg dose, demonstrated compelling maximum weight ...

The phase III ACHIEVE-1 study, the first of seven late-stage studies, is evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes (T2D) and inadequate ...

This assay could also identify patients with BE among patients with gastro-oesophageal reflux disease (AUROC: 94.8%, sensitivity: 92.8%, specificity: 85.1%). Conclusion Using ... Disclaimer The ...

This method applies advanced proteome analysis to identify disease mechanisms. For the Alpha-1 study, liver tissue samples from patients in Germany and Denmark were analyzed. "We examined tissue ...

Today, SQUARE ENIX ® and developer poncle announced a collaboration between SaGa Emerald Beyond and the genre-defining gothic-horror action game Vampire Survivors a. Titled “Emerald Diorama,” this ...

Designed to test VLP Peanut’s safety and tolerability, the PROTECT phase 1 trial is the first study of the vaccine in human beings, including 12 adults with peanut allergy and 12 adults with no ...

The company announced full enrollment in the LIBERATE-1 study and reaffirmed that top-line results should be available in mid-2025. Vivani also expects the results to support the potential ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with moderate-to-severe systemic lupus erythematosus (SLE). The ongoing trial is ...